The symposium “Advancing Amblyopia Care: Innovations in Clinical Trials and Multisensory Approaches in Neuroscience and Auditory Science” concluded successfully in Hong Kong on April 16,2025, with Neu-Direction playing a pivotal role in advancing the dialogue around cutting-edge therapies for amblyopia. Hosted by the Chinese Academy of Sciences Hong Kong Institute for Innovation in Regenerative Medicine and Health (CRMH), the event brought together global leaders in neuroscience and ophthalmology, including Prof. K.F. So, member of the Chinese Academy of Science, and Prof. Andrew King, Fellow of the Royal Society, and distinguished scholars from institutions such as the City University of Hong Kong, Shanghai…

Our first pipeline Neu-001,Neu-001, an innovative first-in-class small-molecule drug for treating amblyopia (commonly known as lazy eye), has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone achievement was unveiled at a press conference held on December 17 at the Hong Kong Science Park, marking the first FDA approval for a novel chemical drug developed under Hong Kong’s prestigious InnoHK research platform. The press conference was hosted by Professor Guangjin Pan, Director of the Centre for Regenerative Medicine and  Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences. Key attendees…